Kazia Therapeutics Ltd · NASDAQ:KZIA

Kazia Therapeutics — HC Wainwright Global Investment Conference 2022

18 slides from Kazia Therapeutics's conference presentation, Sep 15, 2022

  1. Slide 1: A Diversified Oncology Drug Development Company

    Exhibit 99.1 A Diversified Oncology Drug Development Company Presentation to HC Wainwright Global Investment Conference New York, NY 14 September 2022 ASX: KZA | NASDAQ: KZIA | Twitter: @KaziaTx

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve substantial risks and uncertainties, not all of which may be known at the time. All state

  3. Slide 3: Company Overview

    Company Overview A late-clinical-stage oncology drug development company Company is dual-listed on NASDAQ Paxalisib EVT801 (KZIA) and ASX (KZA) with market cap around US$ 30 million Brain-penetrant pan-PI3K / mTOR inhibitor Selective VEGFR3 inhibitor • Well-validated class with 5x FDA-approved thera

  4. Slide 4: Pipeline

    Pipeline Two world-class assets in clinical trials licensed from: Paxalisib (formerly GDC-0084) Small molecule, highly potent, brain-penetrant inhibitor of PI3K / mTOR PRECLIN. PHASE 1 PHASE 2 PHASE 3 MARKET Glioblastoma Most common primary brain cancer DIPG Highly aggressive childhood brain cancer

  5. Slide 5: Paxalisib – Kazia's Lead Program

    Paxalisib – Kazia’s Lead Program Multiple signals of clinical efficacy in brain tumors Glioblastoma Brain Metastases DIPG “dramatic reductions in tumor 15.7 months 100% volume and complete resolution of disease symptoms, extending overall survival overall response rate overall survival” in newly-dia

  6. Slide 6: Operating Model

    Operating Model In-licensing advanced assets drives earlier value realization A Proven Strategy Jun 2010 – licensed niraparib from Merck ® Mar 2017 – Zejula (niraparib) approved by FDA License under- Develop value Partner for Dec 2018 – Tesaro acquired by GSK valued assets through late-stage from la

  7. Slide 7: Leadership

    Leadership 160+ years of international drug development experience Board Management Team Iain Ross Dr James Garner Chairman Chief Executive Officer & Executive Director Executive and Board roles in pharma Physician / MBA; Extensive drug and small biotech development experience Bryce Carmine Dr John

  8. Slide 8: Scientific Advisory Board

    Scientific Advisory Board World-leading experts in brain cancer Priscilla K Brastianos, MD John de Groot, MD Alan Olivero, PhD Patrick Y Wen, MD Associate Professor of Medicine Division Chief, Neuro-Oncology Drug Development Consultant Professor of Neurology Harvard Medical School UCSF Harvard Medic

  9. Slide 9: Paxalisib is one of the most broadly potent PI3K inhibitors in the global pipeline

    Paxalisib is one of the most broadly potent PI3K inhibitors in the global pipeline Paxalisib Among Most Potent PI3K Inhibitors Growth factor receptors (e.g. EGFR, HER2) IC (nM) 50 Idealisib (Gilead) p110a p110b p110g p110d mTORC PI3K 1/2 Alpelisib (Novartis) Paxalisib 2 46 10 3 70 Idelalisib 820 565

  10. Slide 10: The PI3K inhibitor class is well-established, but paxalisib is unique

    The PI3K inhibitor class is well-established, but paxalisib is unique in its ability to cross the blood-brain barrier Zydelig Aliqopa Copiktra Piqray Ukoniq paxalisib (idelalisib) (copanlisib) (duvelisib) (alpelisib) (umbralasib) FDA Approved FDA Approved FDA Approved FDA Approved FDA Approved In pi

  11. Slide 11: Phase II study of paxalisib mono-therapy in newly-diagnosed GBM

    Phase II study of paxalisib mono-therapy in newly-diagnosed GBM provides robust signal of clinical efficacy Progression-Free Survival (PFS) Overall Survival (OS) (n=30) (n=30) Median PFS: 8.6 months (6.6-11.0) Median OS: 15.7 months (11.1-19.1) Comparator figure for existing therapy: 5.3 months Comp

  12. Slide 12: Efficacy signal is corroborated by comparative reference data points

    Efficacy signal is generally corroborated by comparison against multiple comparative reference data points Study Year n OS (95% CI) Applicability Comments Kazia Phase II Study 2022 30 15.7 (11.1-19.1) EORTC-NCIC Pivotal study that led to the approval of 2005 60 12.7 (11.6-14.4) Good Hegi et al. temo

  13. Slide 13: Safety Profile in the phase II clinical study in GBM patients

    Safety Profile in the phase 2 clinical study in GBM patients is generally mild to moderate, reversible, and manageable Number of Patients at Any Dose (n=30) Experiencing AEs ‘Possibly’ or ‘Likely’ Related to Paxalisib (affecting ≥10% of patients) Term Gr 1 Gr 2 Gr 3 Gr 4 Total (%) Fatigue 3 13 2 18

  14. Slide 14: GBM AGILE international pivotal study is underway

    GBM AGILE international pivotal study is underway Sponsored by GCAR with support of GBM key opinion leaders Key Points Regorafenib Bayer • A ‘platform study’, run independently of individual 3 Paxalisib companies, designed to expedite Kazia Therapeutics Economies of scale the approval of new drugs f

  15. Slide 15: GBM AGILE was designed as a two-stage study

    GBM AGILE was designed as a two-stage study; first stage may provide sufficient data for registration OVERALL STUDY DESIGN up to 150 patients 50 patients Stage 1 (‘Exploratory’) Stage 2 (‘Confirmatory’) Full FDA Approval Graduation Analysis POTENTIAL OUTCOMES FOR PAXALISIB, GIVEN DECISION IN AUGUST

  16. Slide 16: Financial Metrics

    as at 30 JUN 22 Financial Metrics Lean operating model drives financial efficiency Share Price (US$) 14.00 Market Capitalisation US$ 60M Listing 12.00 ASX (primary) KZA NASDAQ (ADSs @ 1:10 ratio) KZIA 10.00 Shares on Issue 138M NBI Average Daily Volume (12 months) $525,000 Nasdaq Biotech Index 8.00

  17. Slide 17: CY2022 Milestones and Newsflow

    CY2022 Milestones and Newsflow Multiple catalysts across two clinical programs Open GBM AGILE paxalisib arm to recruitment in EU 1H CY2022 ✓ Commence recruitment to paxalisib phase II GBM study at Weill Cornell 1H CY2022 ✓ Preclinical data for paxalisib in AT/RT presented at AACR (April 2022) 1H CY2

  18. Slide 18: www.kaziatherapeutics.com [email protected]

    www.kaziatherapeutics.com [email protected]

Kazia Therapeutics — HC Wainwright Global Investment Conference 2022 on 6ix